SC
TPST icon

Sophrosyne Capital’s Tempest Therapeutics TPST Stock Holding History

Sophrosyne Capital’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3
Closed -$323K – 20
2015
Q1 		$323K Sell
3
-3
-50% -$399K 0.55% 27
2014
Q4 		$767K Sell
6
-13
-68% -$952K 1.18% 22
2014
Q3 		$922K Hold
19
– – 1.09% 30
2014
Q2 		$510K Hold
19
– – 0.52% 37
2014
Q1 		$498K Buy
+19
New +$539K 0.44% 45

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
OH
Orbis Holdings Hamilton, Bermuda $12.8B AUM 8.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sophrosyne Capital's TPST Position: Q2 2015 in Review

Sophrosyne Capital sold out of Tempest Therapeutics (TPST) in Q2 2015, closing a stake of 3 shares — an estimated $323K sold.

Sophrosyne Capital first reported a position in TPST in Q1 2014 and held it in 5 quarters. The position peaked at $922K in Q3 2014. 92 funds tracked by Wall St. Rank hold TPST as of Q2 2015.

  • Sophrosyne Capital reported no remaining Tempest Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Sophrosyne Capital sold 3 Tempest Therapeutics shares in Q2 2015, an estimated $323K.
  • Sophrosyne Capital first reported a position in Tempest Therapeutics in Q1 2014 and held it in 5 quarters.
  • Sophrosyne Capital's Tempest Therapeutics position peaked at $922K in Q3 2014.
  • 92 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2015.

Based on Sophrosyne Capital's 13F filing for Q2 2015, filed 14 Aug 2015.